John Duncan Higgons, Director at Jounce Therapeutics, Inc. (JNCE), bought 6,700 shares at $16.00 ($107K) on 2017-02-01, disclosed to the SEC on 2017-02-02.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| JNCE | SELL | 2021-02-18 | $2K | — | Filing → |
| JNCE | SELL | 2021-01-22 | $20K | — | Filing → |
| JNCE | SELL | 2020-01-08 | $12K | — | Filing → |